Physician profile
Cindy S Yip
NPI 1710364443
$2,979.98
in general payments reported to CMS, 2019-2025
23 companies · $573 in 2025
The $573 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $567 · 2023: $1,409 · 2024: $432 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,382 · Education: $30.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,382.36 |
| Education | $30.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $464.68 | 2022-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $444.76 | 2022-2024 | Farxiga, Lokelma, Breztri |
| Lilly USA, LLC | $382.84 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $252.57 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $189.34 | 2022-2025 | Rexulti |
| Travere Therapeutics, INC. | $188.32 | 2025 | Filspari |
| Amgen INC. | $186.32 | 2022-2025 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $144.02 | 2022-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $108.43 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $103.25 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.87 | 2023 | |
| Calliditas Therapeutics US INC. | $74.48 | 2023 | Tarpeyo |
| Pfizer INC. | $69.03 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.82 | 2023 | Jardiance, Stiolto Respimat |
| Sanofi-Aventis U.S. LLC | $49.42 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Oxygen Therapy INC. | $27.82 | 2023 | Topical Oxygen Chamber For Extremities |
| Daiichi Sankyo INC. | $27.26 | 2022 | |
| Merck Sharp & Dohme LLC | $24.58 | 2023 | Verquvo, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.11 | 2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $19.68 | 2023 | Eliquis |
| Dexcom, INC. | $17.98 | 2023 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $15.72 | 2023 | Sapien 3 Ultra Resilia |
| Xeris Pharmaceuticals, INC. | $15.68 | 2023 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Yip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.